( MENAFN - GlobeNewsWire - Nasdaq) - Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronary artery disease -– FFRCT further validated in new study demonstrating diagnostic accuracy and greater ability than CCTA alone to rule out hemodynamically significant stenoses in patients with high-risk NSTE-ACS WASHINGTON, Oct. 27, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc. , the global leader in non-invasive artificial intelligence (AI) heart care solutions, today announced seven-year data confirming the use of HeartFlow's AI-enabled fractional flow reserve computed tomography (FFRCT) and Plaque Analysis in the assessment of long-term risk of coronary artery disease (CAD) in clinically stable, symptomatic patients.
The data show the HeartFlow platform provides clinicians with the insights needed to anticipate and mitigate adverse events, including myocardial infarctions, in symptomatic patients with stable chest pain. The data were presented at the 36th annual Transcatheter Cardiovascular Therapeutics® (TCT) conference in Washington, D.C.
ADVANCE-DK is data from a subset of the larger ADVANCE Registry , which prospectively evaluated the use of a coronary computed tomography angiography (CCTA) and FFRCT diagnostic pathway in real-world settings to determine the impact on decision-making, downstream invasive coronary angiography (ICA), revascularization, and major adverse cardio.
